Continuous oral valproate showed no clear difference in recurrent seizure at 6 months compared with placebo or no treatment (low certainty).
Intermittent oral or rectal diazepam may leads to lower recurrent seizure at 18 months compared with placebo or no treatment (low certainty).
Continuous oral valproate showed no clear difference in recurrent seizure at 12 months compared with placebo or no treatment (low certainty).
It is very uncertain whether continuous oral valproate changes recurrent seizure at 18 months compared with placebo or no treatment (very low certainty).
Continuous oral valproate showed no clear difference in recurrent seizure at 24 months compared with placebo or no treatment (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Intermittent oral or rectal diazepam leads to lower recurrent seizure at 24 months compared with placebo or no treatment (high certainty).
Intermittent oral or rectal diazepam may leads to lower recurrent seizure at 36 months compared with placebo or no treatment (low certainty).
Intermittent oral or rectal diazepam probably leads to lower recurrent seizure at 48 months compared with placebo or no treatment (moderate certainty).
It is very uncertain whether intermittent oral or rectal diazepam changes recurrent seizure at 60 months or greater compared with placebo or no treatment (very low certainty).
Continuous phenobarbital probably leads to lower recurrent seizure at 6 months compared with placebo or no treatment (moderate certainty).
Continuous phenobarbital may leads to lower recurrent seizure at 12 months compared with placebo or no treatment (low certainty).
The review found no eligible studies for this question.
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… may leads to lower cure compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (low certainty).
It is very uncertain whether glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… changes adverse events compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.